Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
Institutional investors interested in meeting with members of Satellos’s senior management team during the conference may contact their representative at
About
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305400037/en/
Investors:
Business Development:
Media:
Source: